Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting ...Middle East

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients...

Hence then, the article about lilly to present initial clinical data for first in class type ii jak2 inhibitor in patients with previously treated myelofibrosis at the 2026 eha annual meeting was published today ( Saturday 13/06/2026 - 06:18 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting )

Also on site :

• Country Star Makes Billboard Chart History With No. 1 Hit Song Lasting 28 Weeks
• Innoscience Secures Final Victory in Patent Lawsuit as China's Supreme Court Upholds Injunction Against Infineon GaN Products
• Older runners defy age in Kenya’s central highlands